

**BRAWN**



D5937

CIN NO.: L74899DL1985PLC022468

Date: 12<sup>th</sup> February, 2018

To,

Department of Corporate Services  
BSE Limited  
25<sup>th</sup> Floor, P.J. Towers,  
Dalal Street,  
Mumbai- 400001

Dear Sir/ Madam,

**Sub: Outcome of 7<sup>th</sup> Board Meeting for Financial Year 2017-18**

**Ref: BSE Scrip Code: 530207**

We would like to inform you that the 7<sup>th</sup> / 2017-18 meeting of the Board of Directors held today i.e, **Monday, 12th February, 2018** commenced at **01:00 P.M** and concluded at **05:00 P.M.** at the Registered Office of the Company situated at 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002, inter alia considered the following:

1. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, approved the standalone un-audited Financial Results of the Company for the quarter and nine months ended on 31<sup>st</sup> December, 2017. A copy of the aforesaid results along with extract of the same is enclosed herewith as **Annexure- I.**
2. Limited Review Report on Standalone Un- audited Financial Results for quarter and nine months ended on 31<sup>st</sup> December, 2017 obtained from Statutory Auditor has also been taken on record and a copy of the same is enclosed herewith as **Annexure- II.**

Kindly acknowledge the receipt and take on record.

Thanking You,

Yours truly,

For and On behalf of

Brawn Biotech Limited

For Brawn Biotech Limited

Mamta Surkali  
Company Secretary

Encl: As above

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*...for better life*


Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



**BRAWN**

48FED

ANNEXURE-I

CIN NO.: L74899DL1985PLC022468

BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002						
STATEMENT OF STANDALONE UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER and NINE MONTHS ENDED ON 31ST DECEMBER, 2017						
Sr. No.	Particulars	Quarter Ended		9 months ended		Rs. In Lac
		31.12.2017	30.09.2017	31.12.2016	31.12.2017	31.12.2016
		Un-audited	Un-audited	Un-audited	Un-audited	Audited
1	Revenue from operations					
	Revenue from operations	1,677.33	1,159.52	1,607.25	3,931.18	4,337.04
	Other Income	22.85	18.04	24.49	56.83	72.93
	<b>Total Revenue</b>	<b>1,700.18</b>	<b>1,177.55</b>	<b>1,631.74</b>	<b>3,988.01</b>	<b>4,409.97</b>
2	Expenses					
a	Cost of material consumed	-	-	-	-	-
b	Purchase of stock-in-trade	1,512.23	988.81	1,433.15	3,498.50	3,819.60
c	Change in inventories of finished goods, work in progress and stock in trade	(13.20)	10.01	(7.74)	(5.78)	14.85
d	Employee Benefit expenses	99.86	56.43	45.16	207.88	139.29
e	Depreciation and amortisation expenses	0.80	0.80	0.82	2.38	2.33
f	Finance Cost	0.67	0.55	0.78	1.74	1.87
g	Other expenses	45.38	36.22	119.86	118.62	336.60
	<b>Total Expenses</b>	<b>1,645.75</b>	<b>1,092.81</b>	<b>1,592.02</b>	<b>3,823.35</b>	<b>4,314.54</b>
3	Profit from Operation before Other Income, exceptional and extra-ordinary items (1-2)	54.43	84.74	39.72	164.66	95.43
4	Other Income	-	-	-	-	0.55
5	Profit from ordinary activities before exceptional items (3-4)	54.43	84.74	39.72	164.66	95.98
6	Exceptional Items	-	-	-	-	57.60
7	Profit from ordinary activities before tax (5-6)	54.43	84.74	39.72	164.66	153.58
8	Tax Expenses	15.94	27.96	13.40	52.62	37.50
9	Profit (Loss) for the period from continuing operations (7-8)	38.49	56.78	26.32	112.04	116.08
10	Profit/(loss) from discontinuing operations	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-	-
13	Profit (Loss) for the period (9+12)	38.49	56.78	26.32	112.04	116.08
14	Other Comprehensive Income	(3.85)	0.33	-	(3.65)	-
	<b>Total Comprehensive Income</b>	<b>34.64</b>	<b>57.11</b>	<b>26.32</b>	<b>108.39</b>	<b>139.25</b>
15	Details of equity share capital	300.03	300.03	300.03	300.03	300.03
	Paid-up equity share capital					
	Face value of equity share capital					
16	Reserve excluding Revaluation Reserve	446.05	411.41	368.64	446.05	368.64
17	Earnings per share					
i	Basic earnings per share	1.15	1.90	0.88	3.61	3.87
ii	Diluted earnings per share	1.15	1.90	0.88	3.61	3.87

**NOTES :-**

- Results for the quarter and nine months ended 31st december, 2017 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 12th February 2018.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. Beginning 1<sup>st</sup> April, 2017, the Company has for the first time adopted Ind AS with Transition date of 1<sup>st</sup> April, 2016.
- The Statutory Auditors carried out the "Limited Review" of the results for the quarter and nine months ended 31st December, 2017. The Ind AS Compliant financial results pertaining to the corresponding quarter and nine months ended 31<sup>st</sup> December, 2016, have not been subjected to limited review or audit. However, the management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Unaudited Financial Results for the quarter and nine months ended 31.12.2017 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).

**BRAWN BIOTECH LTD.**


(Formerly Known as Brawn Pharmaceuticals Ltd.)

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208


Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



... for better life



**BRAWN**

4E674

CIN NO.: L74899DL1985PLC022468

6 Reconciliation between financial results as per previous Indian GAAP and Ind AS for the quarter and nine months ended 31st December, 2016 is as under.

(Rs. In Lac)				
Sr. No.	Description	Sub Notes	Quarter ended 31st December, 2016	Nine month ended 31st December, 2016
	Net Profit as per previous Indian GAAP			
1	Fair Valuation adjustments for financial assets		26.32	116.08
2	Actuarial loss on employee defined benefits plan recognised in OCI	(i)	-	-
3	Deferred Tax impact on Ind AS adjustments	(ii)	-	-
	Net Profit as per Ind AS	(iii)	-	-

**Sub Notes:**

- (i) Under Indian GAAP, current investments were measured at lower of cost and net realisable value. Under Ind AS, financial assets other than those valued at amortised cost are subsequently item that will not be reclassified to profit or loss under the Statement of other Comprehensive Income (OCI).
- (ii) Under Indian GAAP, re-measurement gain/loss on defined benefits plans is charged to the Statement of Profit and Loss. Under Ind AS, such re-measurement gain/loss is reported as an item that will not be reclassified to profit or loss under the Statement of other Comprehensive Income (OCI).
- (iii) Under India GAAP, deferred taxes are recognised using Income statement approach i.e. reflecting the tax effects of timing differences between accounting income and taxable income for the period. The impact of transition adjustments together with Ind AS mandate of using balance sheet approach (against income approach under Indian GAAP) for computation of deferred tax has resulted in consequential impact to Statement of Profit and Loss.
- 7 Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board  
For Brawn Biotech Limited

Brij Raj Gupta  
Managing Director  
DIN NO. 00974969  
Date : 12.02.2018  
Place: Delhi

**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

*...for better life*


**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: solution@brawnbiotech.com

**Works :** 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



**BRAWN**

51DDF

CIN NO.: L74899DL1985PLC022468

**BRAWN BIOTECH LIMITED**

CIN:L74899DL1985PLC022468

REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002

Extract of Standalone unaudited Financial Results for the quarter and nine months ended 31st December 2017

(Rs. In Lakhs)

Sr. No	Particulars	Standalone		
		Quarter ended 31.12.2017	9 months ended 31.12.2017	Quarter ended 31.12.2016
		Un-audited	Un-audited	Un-audited
1	Total income from operation	1,700.18	3,988.01	1,631.74
2	Net Profit/(Loss) from ordinary activities after tax	38.49	112.04	26.32
3	Net Profit/(Loss) for the period after tax (after extraordinary items)	38.49	112.04	26.32
4	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income]	34.64	108.39	26.32
5	Equity Share Capital	300.03	300.03	300.03
6	Reserve (excluding Revaluation Reserves as shown in the balance sheet of previous year)	446.05	446.05	368.64
7	Earning per share (before extraordinary items)(not annualised): (of rs. 10 each)			
	(a) Basic (Rs.)	1.15	3.61	0.88
	(b) Diluted (Rs.)	1.15	3.61	0.88
8	Earning per share (after extraordinary items)(not annualised): (of rs. 10 each)			
	(a) Basic (Rs.)	1.15	3.61	0.88
	(b) Diluted (Rs.)	1.15	3.61	0.88

**NOTES :-**

- Results for the quarter and nine months ended 31st december, 2017 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 12th February 2018.
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable. Beginning 1<sup>st</sup> April, 2017, the Company has for the first time adopted Ind AS with Transition date of 1<sup>st</sup> April, 2016.
- The Statutory Auditors carried out the "Limited Review" of the results for the quarter and nine months ended 31st December, 2017. The Ind AS Compliant financial results pertaining to the corresponding quarter ended 31<sup>st</sup> December, 2016, have not been subjected to limited review or audit. However, the management has exercised necessary due diligence to ensure that the financial results provided a true and fair view of its affairs.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Unaudited Financial Results for the quarter and nine months ended 31.12.2017 are available on company's website [www.brawnbiotech.com](http://www.brawnbiotech.com) and BSE website [www.bseindia.com](http://www.bseindia.com).

Place: Delhi

Date: 12.02.2018

For and on behalf of Board  
For Brawn Biotech LimitedBrij Raj Gupta  
Managing Director  
DIN NO. 00974969**BRAWN BIOTECH LTD.**

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

**Regd. Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com), Website : [www.brawnbiotech.com](http://www.brawnbiotech.com)

**Export Office :** 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

**Corporate Office :** Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462  
Email: [solution@brawnbiotech.com](mailto:solution@brawnbiotech.com)

**Works :** 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48





**Independent Auditor's Report on Quarterly Standalone Financial Results of BRAWN BIOTECH LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**


To,  
The Board of Directors of  
Brawn Biotech Limited

We have reviewed the accompanying statement of Unaudited Financial Results of **Brawn Biotech Limited** (the "Company") for the quarter and nine months ended 31<sup>st</sup> December 2017, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rajiv Udai & Associates  
Chartered Accountants  
Firm Registration No. 18764N

  
Rajeev Jain  
(Partner)  
(Membership No. 99767)



Place: Delhi  
Date: 12.02.2018